Cover Image
Market Research Report

Global Staphylococcal Infection Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 835755
Published Content info 126 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Staphylococcal Infection Drugs Market 2019-2023
Published: April 29, 2019 Content info: 126 Pages
Description

About this market

Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market. Technavio' s analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.

Market Overview

Increasing incidence of staphylococcal infections

The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.

Lack of vaccines and new drug classes

Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.

For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures. Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR31241

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Beta-lactams - Market size and forecast 2018-2023
  • Peptides - Market size and forecast 2018-2023
  • Quinolones - Market size and forecast 2018-2023
  • Macrolides - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Bayer AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of vendors classification

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global infectious disease treatment market
  • Exhibit 02: Segments of global infectious disease treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Beta-lactams - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Beta-lactams - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Peptides - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Peptides - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Quinolones - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Quinolones - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Macrolides - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Macrolides - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by product
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in North America
  • Exhibit 42: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Top 3 countries in Europe
  • Exhibit 45: Key leading countries
  • Exhibit 46: Market opportunity
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: Allergan Plc - Vendor overview
  • Exhibit 54: Allergan Plc - Business segments
  • Exhibit 55: Allergan Plc - Organizational developments
  • Exhibit 56: Allergan Plc - Geographic focus
  • Exhibit 57: Allergan Plc - Segment focus
  • Exhibit 58: Allergan Plc - Key offerings
  • Exhibit 59: Bayer AG - Vendor overview
  • Exhibit 60: Bayer AG - Business segments
  • Exhibit 61: Bayer AG - Organizational developments
  • Exhibit 62: Bayer AG - Geographic focus
  • Exhibit 63: Bayer AG - Segment focus
  • Exhibit 64: Bayer AG - Key offerings
  • Exhibit 65: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 66: GlaxoSmithKline Plc - Business segments
  • Exhibit 67: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 68: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 69: GlaxoSmithKline Plc - Segment focus
  • Exhibit 70: GlaxoSmithKline Plc - Key offerings
  • Exhibit 71: Merck & Co. Inc. - Vendor overview
  • Exhibit 72: Merck & Co. Inc. - Business segments
  • Exhibit 73: Merck & Co. Inc. - Organizational developments
  • Exhibit 74: Merck & Co. Inc. - Geographic focus
  • Exhibit 75: Merck & Co. Inc. - Segment focus
  • Exhibit 76: Merck & Co. Inc. - Key offerings
  • Exhibit 77: Pfizer Inc. - Vendor overview
  • Exhibit 78: Pfizer Inc. - Business segments
  • Exhibit 79: Pfizer Inc. - Organizational developments
  • Exhibit 80: Pfizer Inc. - Geographic focus
  • Exhibit 81: Pfizer Inc. - Segment focus
  • Exhibit 82: Pfizer Inc. - Key offerings
  • Exhibit 83: Validation techniques employed for market sizing
  • Exhibit 84: Definition of vendors classification
Back to Top